The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of goserelin plus fulvestrant 500mg
comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and
perimenopausal HR+ advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital Affiliated to Military Medical Science, Beijing